EMJ Podcast: Insights For Healthcare Professionals

In this episode, Satish Raj and Gert van Dijk explore the diagnosis, clinical burden, and management of orthostatic hypotension. The discussion examines how low blood pressure affects daily functioning, the importance of accurate diagnosis, and current treatment approaches.

Key Discussion Themes

• Definitions and subtypes of orthostatic hypotension

• Differential diagnosis and the role of tilt-table testing

• Impact on quality of life and daily functioning

• Current treatment landscape and clinical guidelines

• Unmet needs and future research priorities

In this episode, Aaron Phillips discusses haemodynamic instability following spinal cord injury, with particular focus on autonomic dysreflexia. The conversation reviews the neuronal mechanisms underpinning autonomic dysfunction, the clinical burden of hypertensive and hypotensive complications, and current management strategies. The episode also explores emerging therapeutic approaches, including the development and evaluation of implantable systems designed to restore haemodynamic stability.

Key Discussion Themes

• Definition and clinical features of haemodynamic instability

• Autonomic dysreflexia: mechanisms and patient impact

• Chronic hypertensive and hypotensive complications

In the final episode of the series, David Goldstein examines orthostatic hypotension as a manifestation of autonomic failure in Parkinson's disease. The discussion explores the pathophysiology of cardiac noradrenergic deficiency, its identification and clinical implications, and current management approaches. The episode also considers the prognostic significance of orthostatic hypotension in Parkinson's disease and potential future directions in research and patient care.

Key Discussion Themes

• Autonomic failure in Parkinson's disease

• Cardiac noradrenergic deficiency: definition and identification

• Clinical consequences, including falls and cognitive impairment

• Mechanistic insights into sympathetic denervation

• Current treatment approaches and guideline considerations

• Future research priorities

Debbie Palmer joins host Catherine Glass to explore how maternal diet shapes fetal immune development and influences allergy risk. This episode unpacks key nutrients, timing of dietary exposures, and findings from randomised trials that challenge conventional pregnancy nutrition advice.

Timestamps:

01:22 – Maternal diet

02:59 – Mid-pregnancy versus preconception

03:53 – Food groups

04:28 – Prebiotic supplements

05:30 – Pregnancy cravings

In this rapid-fire episode, Debbie Palmer answers key questions on allergy prevention, from pregnancy nutrition myths and early allergen introduction to common misconceptions among clinicians and parents. A concise overview of cutting-edge thinking in just a few minutes.

In the final episode of this series, Leslie Cho focuses on prevention. From lifestyle interventions and pregnancy-related risk to menopause, brain health, and cholesterol management, she shares practical strategies clinicians can use today to improve long-term cardiovascular outcomes for women.

Timestamps:

01:02 – Lifestyle interventions

02:30 – Gestational hypertension

07:06 – Menopause

08:35 – Brain health

12:00 – Cholesterol levels

13:59 – Key message

This episode has been funded by Sun Pharmaceutical Industries, Inc. Please see full Prescribing Information and the Patient Information for clascoterone cream 1%.

Sebum plays a central role in acne pathogenesis. In this AMJ Rapid Review, Zoe Diana Draelos, MD, breaks down what new 52-week findings with clascoterone cream 1% may mean for everyday dermatology practice.

In under 15 minutes, learn:

• How did the study objectively measure sebum, and what makes that approach clinically useful?
• What did the 52-week results reveal about changes over time, beyond what you see in the first few visits?
• How might sebum trends relate to standard acne assessments in longer-term follow-up?
• What practical expectations and counseling tips can help patients stay on track with treatment?

Speaker:

Zoe Diana Draelos, MD

Dermatology Consulting Services, PLLC, North Carolina, USA

IMPORTANT SAFETY INFORMATION

Indication

What is WINLEVI cream?

WINLEVI (clascoterone) cream 1% is a prescription medicine used on the skin (topical) to treat acne vulgaris in people 12 years of age and older.

It is not known if WINLEVI cream is safe and effective in children under 12 years of age.

Important Patient Information

Before using WINLEVI cream, tell your healthcare provider about all of your medical conditions, particularly if you:

• have skin problems, including eczema, cuts or sunburn
• are pregnant or plan to become pregnant. It is not known if WINLEVI cream will harm your unborn baby
• are breastfeeding or plan to breastfeed. It is not known if WINLEVI cream passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with WINLEVI cream

WINLEVI cream is for use on the skin only (topical). Do not use WINLEVI cream in or on your eyes, mouth, or vagina. Do not use WINLEVI cream for a condition for which it was not prescribed. Do not give WINLEVI cream to other people, even if they have the same symptoms you have. It may harm them.

What are the possible side effects of WINLEVI cream?

WINLEVI cream can cause serious side effects, including:

• local skin reactions. WINLEVI cream may cause local skin irritation including itching, burning, skin redness or peeling.
• symptoms of a disorder where the adrenal gland does not make enough of certain hormones (adrenal insufficiency) during treatment with WINLEVI. Your healthcare provider may stop your treatment with WINLEVI if you develop any adrenal problems.

The most common side effects of WINLEVI cream include reddening, scaling or dryness, and itching of the skin being treated.

These are not all of the possible side effects of WINLEVI cream.

Tell your healthcare provider about the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or to Sun Pharmaceutical Industries, Inc. by calling 1-800-818-4555.

Please see full Prescribing Information and the Patient Information.

Why does cardiovascular data so often fail women? In Part 2, Leslie Cho unpacks how trial design, symptom bias, and underdiagnosis of microvascular disease distort care for women, and what the evidence actually tells us about diagnosis, imaging, and treatment.

Timestamps:

00:50 – Misinterpretations

02:22 – Younger women

03:10 – Symptoms bias

05:05 – Microvascular dysfunction

07:17 – Cardiac PET

In this episode of Onc Now, Jonathan Stevenson explores the evolving field of orthopaedic oncology, highlighting the clinical challenges and innovations shaping the care of patients with bone and soft-tissue sarcomas. The conversation covers key hurdles in limb-salvage surgery, the ongoing challenge of prosthetic joint infection, and promising developments in translational research. He also shares insights into multidisciplinary collaboration, the vision behind future metastatic trials, and advice for the next generation of orthopaedic surgeons.

Timestamps:

00:00 - Introduction

02:16 - Overview of orthopaedic oncology challenges

08:40 - Pressing hurdles in limb-salvage surgery

13:27 – Prosthetic joint infections

17:00 - Promising developments in research

19:10 - Vision of NIHR metastatic trial

22:12 - Multidisciplinary care approach strategies

24:39 - Advice for early-career surgeons

26:22 - Transformative changes next decade

28:12 - Three 'magic wishes' for future care

In this first deep dive, Leslie Cho explores how lipidology and hormone therapy intersect in women's cardiovascular care. Drawing on major guideline work and trial data, she explains how clinicians should approach menopausal hormone therapy, complex lipid disorders, microvascular disease, and emerging therapies through a precision lens.

Timestamps:

01:10 – Menopausal hormone therapy

03:45 – Lipid-lowering therapy

05:55 – Microvascular disease

07:55 – Testosterone therapy